Zheshang** recently released a research report, expressing optimism about the medium and long-term investment opportunities in the innovative drug industry. The report points out that with the introduction and continuous optimization of the simplified renewal rules for medical insurance negotiations, the payment environment for innovative drugs continues to improve, and the innovative drug industry has entered a virtuous cycle of development.
The innovative drug industry has always been an important part of the pharmaceutical industry, and its research and development requires a lot of capital and time investment, and has the characteristics of high risk and high return. In recent years, with the continuous progress of medical technology and the development of the pharmaceutical industry, the R&D and production of innovative drugs have become the key development direction of leading countries and enterprises.
China** has also been vigorously supporting the development of the innovative drug industry. From a policy perspective, the introduction and continuous optimization of the simple renewal rules for medical insurance negotiations have provided a more stable environment for the payment of innovative drugs. In addition, ** has also introduced a series of policies to encourage the research and development of innovative drugs, including tax incentives, financial subsidies, etc., which provide strong support for the development of the innovative drug industry.
From the perspective of the market, with the improvement of people's health awareness and the increase of medical demand, the market for innovative drugs has great potential. According to Tianyancha data, there are currently more than 1,300 innovative drug-related companies in China, including some powerful listed companies. The R&D and production capacity of these companies has been continuously improved, providing more high-quality innovative drug products for the market.
Zheshang** believes that there are still great investment opportunities in the innovative drug industry in the future. First of all, with the continuous progress of technology and policy support, the threshold for R&D and production of innovative drugs will continue to be lowered, and more companies will enter this field to provide more diversified products and services for the market. Secondly, with the continuous improvement of the payment environment and the increase in the stability of innovative drugs, the commercialization prospects of innovative drugs will be broader. Finally, with the gradual control of the global epidemic and the recovery of the economy, the overall development of the pharmaceutical industry will be more stable and sustainable.
To sum up, Zheshang is optimistic about the medium and long-term investment opportunities in the innovative drug industry. From the perspectives of policy, market and technology, the innovative drug industry has broad development prospects and investment value. However, at the same time, investors need to pay close attention to market dynamics and policy changes, and do a good job in risk control and asset allocation. (Data support: Tianyancha).